Publications by authors named "Scot Ebbinghaus"

48Publications

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

J Clin Oncol 2018 06 28;36(17):1668-1674. Epub 2017 Dec 28.

Caroline Robert, Gustave Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Adil Daud, University of California, San Francisco, San Francisco, CA; Jedd D. Wolchok, Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, NY; Anthony M. Joshua, The Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H Lee Moffitt Cancer Center, Tampa; Richard W. Joseph, Mayo Clinic Cancer Center-Florida, Jacksonville, FL; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, UPMC Hillman Cancer Center, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead; Melanoma Institute Australia, Wollstonecraft; and Macquarie University, MQ Health, Health Sciences Centre; Peter Hersey, University of Sydney, Sydney, New South Wales, Australia; Jin Zhang, James Anderson, Scott J. Diede, and Scot Ebbinghaus, Merck & Co., Inc., Kenilworth, NJ; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.6270
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.6270DOI Listing
June 2018

Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice Experiment.

Cancer Nurs 2019 Jan/Feb;42(1):E52-E59

Author Affiliations: Merck & Co, Inc, Kenilworth, New Jersey (Drs Liu and Ebbinghaus); Kantar Health, New York, New York (Dr Witt, Ms Beyer, and Mr Basurto); and Mayo Clinic, Jacksonville, Florida (Dr Joseph).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/NCC.0000000000000557DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286876PMC
January 2020

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

J Immunother 2017 Nov/Dec;40(9):334-340

*Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA †The University of Texas MD Anderson Cancer Center, Houston, TX ‡Memorial Sloan Kettering Cancer Center §Weill Cornell Medical College §§NYU Clinical Cancer Center, New York, NY ∥The Angeles Clinic and Research Institute, Los Angeles ¶Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco ††The John Wayne Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA #Mayo Clinic, Rochester, MN **Mayo Clinic, Jacksonville, FL ‡‡Dana-Farber Cancer Institute, Boston, MA ∥∥Yale Cancer Center, New Haven, CT ¶¶Clinigen, Weybridge, UK ##Merck & Co. Inc., Kenilworth, NJ ***Duke Cancer Institute, Durham, NC.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00002371-900000000-9951
Publisher Site
http://dx.doi.org/10.1097/CJI.0000000000000186DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647109PMC
May 2018

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

J Clin Oncol 2016 12 31;34(34):4102-4109. Epub 2016 Oct 31.

Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.2477
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.2477DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562434PMC
December 2016

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.

Eur J Cancer 2016 11 2;67:46-54. Epub 2016 Sep 2.

Department of Medicine, Division of Hematology-Oncology, Jonsson Comprehensive Cancer Center (JCCC) at the University of California, Los Angeles (UCLA), 10833 Le Conte Ave, Los Angeles, CA 90095, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049163234
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2016.07.018DOI Listing
November 2016

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

J Clin Oncol 2016 05 7;34(13):1510-7. Epub 2016 Mar 7.

F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Richard Kefford, Westmead Hospital, Melanoma Institute Australia, and Macquarie University; Peter Hersey, University of Sydney, Sydney, Australia; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; Adil Daud, University of California San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute; Antoni Ribas, University of California Los Angeles, Los Angeles, CA; Caroline Robert, Gustave-Roussy and Paris-Sud University, Villejuif-Paris-Sud, France; Tara C. Gangadhar, Abramson Cancer Center, Philadelphia, PA; Anthony M. Joshua, Princess Margaret Hospital, Toronto, Ontario, Canada; Roxana Dronca, Mayo Clinic, Rochester, MN; Darcy Hille, Dahai Xue, Xiaoyun Nicole Li, S. Peter Kang, Scot Ebbinghaus, and Andrea Perrone, Merck, Kenilworth, NJ; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.0391DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070547PMC
May 2016

Pembrolizumab.

J Immunother Cancer 2015 18;3:36. Epub 2015 Aug 18.

Department of Medical Oncology, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON M5G 2M9 Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-015-0078-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539882PMC
August 2015

Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).

Cancer Chemother Pharmacol 2013 Oct 7;72(4):909-16. Epub 2013 Aug 7.

Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3008 AE, Rotterdam, The Netherlands,

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s00280-013-2250
Web Search
http://link.springer.com/10.1007/s00280-013-2250-6
Publisher Site
http://dx.doi.org/10.1007/s00280-013-2250-6DOI Listing
October 2013

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.

J Clin Oncol 2010 Jun 10;28(17):2839-46. Epub 2010 May 10.

University of Texas M D Anderson Cancer Center, Thoracic Head and Neck Medicine Clinic, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.25.1991DOI Listing
June 2010

A novel G-quadruplex-forming GGA repeat region in the c-myb promoter is a critical regulator of promoter activity.

Nucleic Acids Res 2008 Apr 5;36(6):1755-69. Epub 2008 Feb 5.

Arizona Cancer Center, University of Arizona, 1515 N. Campbell Ave., Tucson, AZ 85724-5024, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/nar/gkm1069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2330228PMC
April 2008

Mechanism of PNA transport to the nuclear compartment.

Ann N Y Acad Sci 2006 Oct;1082:27-30

Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724-5024, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1196/annals.1348.064DOI Listing
October 2006

PNA-nitrogen mustard conjugates are effective suppressors of HER-2/neu and biological tools for recognition of PNA/DNA interactions.

Bioconjug Chem 2006 Jan-Feb;17(1):214-22

Arizona Cancer Center, University of Arizona, 1515 North Campbell, 85724, Tucson, Arizona, USA.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/abs/10.1021/bc0502964
Publisher Site
http://dx.doi.org/10.1021/bc0502964DOI Listing
September 2006

Evidence for the presence of a guanine quadruplex forming region within a polypurine tract of the hypoxia inducible factor 1alpha promoter.

Biochemistry 2005 Dec;44(49):16341-50

Arizona Cancer Center, University of Arizona, 1515 North Campbell Avenue, Tucson, Arizona 85724-5024, USA.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/abs/10.1021/bi051618u
Publisher Site
http://dx.doi.org/10.1021/bi051618uDOI Listing
December 2005

Peptide nucleic acid conjugates: synthesis, properties and applications.

Curr Top Med Chem 2005 ;5(12):1119-31

Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/156802605774370892DOI Listing
January 2006

Synthesis and evaluation of a triplex-forming oligonucleotide-pyrrolobenzodiazepine conjugate.

Bioconjug Chem 2004 Nov-Dec;15(6):1182-92

Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724-5024, USA.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/abs/10.1021/bc0498673
Publisher Site
http://dx.doi.org/10.1021/bc0498673DOI Listing
April 2005

Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.

Hematol Oncol Clin North Am 2004 Oct;18(5):1143-59, ix-x

Division of Hematology-Oncology, University of Arizona College of Medicine, Arizona Cancer Center, 1515 North Campbell Avenue, Tucson, AZ 85724-5024, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2004.06.003DOI Listing
October 2004

Site-selective DNA binding drugs.

Chem Biol 2003 Oct;10(10):895-7

Arizona Cancer Center, 1515 North Campbell Avenue, Tucson, AZ 85724, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2003.10.004DOI Listing
October 2003